HIGHMARK WHOLECARE

Updated: 08/2025
PARP Approved: 09/2025

Prior Authorization Criteria
Firdapse (amifampridine)

All requests for Firdapse (amifampridine) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a diagnosis of **Lambert-Eaton myasthenic syndrome (LEMS)** and the following criteria is met:

- Must be prescribed by or in consultation with a neurologist
- Must provide documentation of muscle weakness with typical distribution, areflexia, autonomic dysfunction, and **ONE** of the following:
    - Presence of VGCC autoantibodies
    - Electromyograph (EMG) or Nerve Conduction Study (NCS) with adequate repetitive stimulation undertaken in relevant muscles
- Provider attestation that other differential diagnoses such as Myasthenia Gravis have been ruled out
- Provider attestation that the member does not have a history of seizures
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines
- **Initial Duration of Approval:** 3 months
- **Reauthorization criteria**
    - Must provide chart documentation demonstrating improvement or stabilization of muscle weakness from baseline
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

HIGHMARK WHOLECARE

Updated: 08/2025
PARP Approved: 09/2025

FIRDAPSE (AMIFAMPRIDINE) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Wholecare Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (800) 392-1147 Mon – Fri 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	Provider NPI:
Provider Specialty:	Office Contact:
State license #:	Office NPI:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? ☐ Yes ☐ No	Date Medication Initiated:	

Billing Information

This medication will be billed: ☐ at a pharmacy **OR** ☐ medically, JCODE:_____

Place of Service: ☐ Hospital ☐ Provider's office ☐ Member's home ☐ Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis:	ICD Code:

How was the diagnosis confirmed?
- ☐ Presence of VGCC antibodies
- ☐ EMG or nerve conduction study

Does the member have muscle weakness with typical distribution, areflexia, and autonomic dysfunction? ☐ Yes ☐ No

Have other differential diagnoses (e.g. Myasthenia Gravis) been ruled out? ☐ Yes ☐ No

Does the member have a history of seizures? ☐ Yes ☐ No

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

REAUTHORIZATION

Has the member experienced improvement with treatment? ☐ Yes ☐ No

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature	Date